Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H16O6.C11H14N2S |
Molecular Weight | 594.677 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCCN=C1\C=C\C2=CC=CS2.OC(=O)C3=CC4=C(C=CC=C4)C(CC5=C6C=CC=CC6=CC(C(O)=O)=C5O)=C3O
InChI
InChIKey=AQXXZDYPVDOQEE-MXDQRGINSA-N
InChI=1S/C23H16O6.C11H14N2S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-6,9H,3,7-8H2,1H3/b;6-5+
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/monograph/pyrantel-pamoate.html
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/monograph/pyrantel-pamoate.html
Pyrantel is an anthelmintic, which acts as an agonist of nicotinic receptors (AChRs) of nematodes and exerts its therapeutic effects by depolarizing their muscle membranes. It is used to treat a number of parasitic worm infections. This includes ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis and trichinellosis. Common adverse reactions include diarrhea, nausea, vomiting, dizziness, headache and somnolence.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Nicotinic receptors (AChRs) of nematodes |
|||
Target ID: Mouse α2βεδ AChRs Sources: https://www.ncbi.nlm.nih.gov/pubmed/11489460 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Strongid Approved UseDrug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies. Launch Date1990 |
|||
Curative | Strongid Approved UseDrug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies. Launch Date1990 |
|||
Curative | Strongid Approved UseDrug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies. Launch Date1990 |
|||
Curative | Strongid Approved UsePyrantel pamoate is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); large roundworms (Parascaris equorum) and tapeworms (Anoplocephala perfoliata) in horses and ponies. Launch Date1990 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.09 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11348490/ |
13.3 mg/kg single, oral dose: 13.3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRANTEL plasma | Equus caballus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.06 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11348490/ |
13.3 mg/kg single, oral dose: 13.3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRANTEL plasma | Equus caballus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11348490/ |
13.3 mg/kg single, oral dose: 13.3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRANTEL plasma | Equus caballus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. | 2001 Jan |
|
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. | 2003 Sep |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16725288
A modified methyl-thiazolyltetrazolium (MTT) reduction assay revealed good in vitro anthelmintic efficacies against Haemonchus contortus infective larvae for pyrantel tartrate at effective dose 0.1 ug/ul – 0.9 ug/ul.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 357.152
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 520.1872
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 520.2043
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 357.180
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 357.150
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 520.2044
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 357.110
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 520.2042
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
||
|
CFR |
21 CFR 520.2041
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40897057
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
m9336
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
PYRANTEL PAMOATE
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
81BK194Z5M
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
D011716
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
PYRANTEL PAMOATE
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | Description: A pale yellow or yellow powder. Solubility: Practically insoluble in water and methanol R; soluble in dimethyl sulfoxide R; slightly soluble in dimethylformamide R. Category: Anthelmintic. Storage: Pyrantel embonate should be kept in a well-closed container, protected from light. Definition: Pyrantel embonate contains not less than 98.0% and not more than 102.0% of C11H14N2S,C23H16O6, calculated with reference to the dried substance. | ||
|
100000089059
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
8985
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
5281033
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
81BK194Z5M
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
244-837-1
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
C75232
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
355080
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1626223
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
1584003
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
DBSALT001530
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
22204-24-6
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY | |||
|
SUB04132MIG
Created by
admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD